Phase III data on Qudexy in Epilepsy published in Epilepsia-Upsher Smith Labs

Results from Upsher-Smith Laboratories Phase III study of USL 255/Qudexy XR (topiramate extended-release capsules), in patients with Epilepsy, were published in the June issue of Epilepsia. The PREVAIL trial was a randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of Qudexy XR as adjunctive therapy in adult patients with refractory partial-onset seizures (POS).

Findings from the clinical study demonstrated that Qudexy XR (titrated to a maintenance dose of 200 mg/day) significantly improved seizure control. Qudexy XR was associated with a significantly greater median percent reduction in weekly POS frequency compared with placebo (39.5% vs 21.6%, P<0.001) during 11 weeks of treatment. see: once-daily usl 255 as adjunctive treatment of partial-onset seizures: randomized phase 3 study steve s. chung et al. epilepsia 5 june 2014 doi: 10.1111 epi.12660>